EU agency confirms suspension of Merck cholesterol drug
LONDON (Reuters) - Europe's drug regulator has confirmed it is suspending marketing authorizations for Merck & Co's cholesterol drug Tredaptive in Europe after its failure in a major study raised safety concerns.
Merck began recalling the drug, which is also sold under the brand names Pelzont and Trevaclyn, on January 11 and recommended that doctors stop prescribing it.
The medicine had been on the market in 40 countries worldwide, but is not approved in the United States.
The European Medicines Agency said patients currently taking the drug should see their doctor to discuss their treatment.
(Reporting by Kate Kelland; Editing by Hans-Juergen Peters)
- U.S. pledges 3,000 troops to fight Ebola; experts say more needed
- Tesla prevails in top Massachusetts court over direct sales
- Russia needs government investment to avoid recession, says former finance minister
- Ahead of independence vote, Britain pledges state funding to Scotland |
- Stocks turn higher ahead of Fed meeting, oil up
Major U.S. poultry firms are administering antibiotics to their flocks far more pervasively than regulators realize, posing a potential risk to human health. Full Article